The Discounted Cash Flow (DCF) valuation of Cymabay Therapeutics Inc (CBAY) is (20.72) USD. With the latest stock price at 32.48 USD, the upside of Cymabay Therapeutics Inc based on DCF is -163.8%.
Based on the latest price of 32.48 USD and our DCF valuation, Cymabay Therapeutics Inc (CBAY) is a sell. selling CBAY stocks now will result in a potential gain of 163.8%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.7% - 8.4% | 7.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (90.07) - (11.84) | (20.72) |
| Upside | -377.3% - -136.5% | -163.8% |